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Abstract 
 
Background: Myeloperoxidase (MPO) is a marker of plaque vulnerability and a mechanistic bridge between 
inflammation and cardiovascular disease, and thus is a suitable target for therapeutic strategy against 
cardiovascular disease.  Methods: Since hypercholesterolemia is associated with atherosclerosis and 
inflammation, we tested whether MPO serum levels were up-regulated in Familial Hypercholesterolemia 
(FH) and whether acute reduction of total cholesterol (TC) would also reduce MPO concentration. FH 
subjects undergoing  LDL-apheresis (LDL-A) treatment are a paradigmatic clinical model where TC rapidly 
plunges from extremely high to extremely low levels  after  selective LDL removal, and then spontaneously 
rebounds to baseline conditions. This clinical setting allows multiple intra-patient observations at different 
plasma TC concentrations. We measured MPO levels in serum by ELISA tests, and in peripheral leukocytes 
by immunofluorescence, to learn  whether they were affected by the changes in TC levels. Serum MPO was 
measured before and serially up to the 14
th 
day following LDL-A. Results: In both serum and  peripheral 
leukocytes, MPO concentrations were i) higher than in sex- and age-matched healthy controls (p < 0.01); ii) 
decreased with TC reduction; iii) parallel with TC time course; iv) correlated with plasma TC. At  regression 
analysis, plasma TC was the only variable considered that influenced MPO serum levels (β 0.022 ± 0.010, p 
< 0.0001). Conclusions: In FH the MPO serum levels were modulated through changes in the TC 
concentrations carried out by LDL-A. Further study is needed to  determine whether reduced MPO levels 
obtained by LDL-A could have any therapeutic impact. 
 
Key Words: Myeloperoxidase, Familial Hypercholesterolemia (FH), LDL-apheresis, plaque vulnerability, 
peripheral leukocytes, total cholesterol 
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Background 
 
High concentrations of myeloperoxidase (MPO) are associated with atherosclerotic disease, 
marking its presence and severity [1], and is co-localized with its pro-oxidant products in atheroma [2, 3]. 
Subjects with total or subtotal MPO deficiency, a defect with a frequency of about 1 in 2000-4000 
Caucasians, have lower incidence of coronary artery disease (CAD) [4]. A functional polymorphism in the 
MPO promoter gene, which leads to a twofold reduction in MPO expression, is associated with a lower risk 
for angiographic evidence of CAD [5], nonfatal myocardial infarction and cardiac death [6-8]. MPO is 
indicated as a novel marker of plaque vulnerability [9, 10], potentially acting as a mechanistic bridge 
between inflammation and cardiovascular events [11]. 
MPO is a member of the heme peroxidase superfamily and is the most abundant component of primary 
azurophilic granules of leukocytes [12, 13]. MPO is a major antibacterial component that produces 
hypochlorous acid (HOCl), a potent oxidant originating from chlorous ion (Cl
-
) and hydrogen peroxide (H2O2) 
[14, 15], and is secreted following  activation of leukocytes. Leukocyte activation and degranulation have 
been shown in unstable angina [16, 17], whereas leukocyte infiltrates have been documented in coronary 
plaques of patients with acute coronary syndromes [18, 19]. Infiltrating neutrophils contribute to 
destabilizing stable coronary plaques. 
Myeloperoxidase secreted by leukocytes degrades the collagen layer that protects the atheroma from 
erosion or abrupt rupture in the shoulder regions of coronary artery lesions, where the shear stress of 
arterial blood is higher. As a result, plaques highly infiltrated with leukocytes have a thin fibrous cap and 
are vulnerable to erosion or rupture, precipitating events to acute coronary syndromes.  
While there is evidence of a direct role of MPO concentrations within the complex process of plaque 
development and on the chain of events that cause plaque rupture [20-22], the pathological conditions 
involving MPO up-regulation are still unknown, as well as the conditions capable of reducing MPO levels. 
 4
It is known that  high cholesterol concentration triggers all phases of inflammation and patients with 
hypercholesterolemia show elevated markers of inflammation, such as acute phase reactant proteins and 
adhesion molecules [23, 24].  
Based on the above considerations, we addressed the questions whether hypercholesterolemia is 
associated with MPO up-regulation and whether MPO serum levels are affected by cholesterol modulation. 
Therefore, we studied  MPO concentration in subjects with Familial Hypercholesterolemia (FH) undergoing 
LDL (Low Density Lipoprotein) apheresis (LDL-A) treatment. This condition represents a unique clinical 
model where it is possible to achieve rapid, safe and selective marked changes in total cholesterol (TC) 
plasma levels, to perform multiple measurements in the same subject at different cholesterol 
concentrations and to minimize  bias interference in the relationship between cholesterol and 
inflammation markers. 
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Methods 
 
Patients. Eight subjects with heterozygous FH were studied; the diagnosis was based on the 
presence
 
of primary hypercholesterolemia, tendon xanthomata, and family
 
history of 
hypercholesterolemia. All patients had  history of CAD and were free from  any other organic or systemic 
disease able to affect the prognosis (arterial hypertension, diabetes mellitus, obesity, 
hyperhomocysteinemia, smoking, cancer and renal failure). All patients were on pharmacological wash-out 
from the previous 2  months; this period is appropriate for management of statin-related side effects (such 
as  myalgia) as indicated by ACC/AHA/NHLBI clinical advisory on the use and safety of statins [25]. Study 
participants gave their written informed consent and the study protocol received  ethical approval.  
 
LDL-A procedure.  An extracorporeal venous-venous circulation provided a blood flow
 
of 90 to 120 
mL/min; the initial heparin bolus was 1500 IU followed
 
by continuous infusion of 1000 IU/h. Plasma was 
separated by
 
a polysulfone hollow-fiber filter (Sulflux FS-05). Two columns,
 
each containing 150 mL of 
dextran sulfate cellulose, a specific
 
sorbent of apo B–containing lipoproteins (LiposorberLA-15),
 
were 
alternately flushed with plasma and regenerated with 0.7
 
mol/L saline solution followed by rinsing with 
Ringer's solution
 
under control of an automatic adsorption-desorption apparatus
 
(MA-01; Kaneka Co, 
Japan). During a 3.5- to 4-hour period, a total
 
plasma volume of 6.5 to 9.2 L was treated, corresponding to
 
2.5 to 3 times that of each patient's plasma volume [23]. 
Myeloperoxidase, lipid parameters, C3c and C4 complement fraction, haptoglobin, α1-antitrypsin, α2-
macroglobulin, α1-acid glycoprotein, ceruloplasmin and routine laboratory tests, including complete blood 
count, were measured before LDL-A treatment and serially up to the 14
th 
day following each treatment.  
Each patient was consecutively studied three times. 
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First samples after LDL-A were taken immediately before saline infusion to wash out the extracorporeal 
circulation components, in order to avoid any hemodilution effect.  
Finally, to assess  possible absorption by the extracorporeal circuit components, MPO levels were measured 
in samples simultaneously taken from the inlets and the outlets of the plasma separator and the dextran 
sulfate column, both at the beginning and at the end of the LDL-A procedure. 
Pre-treatment values were compared with those  measured in eight healthy control subjects matched for 
age and sex. 
 
Laboratory Analysis. Total cholesterol (TC), triglycerides (TG) and HDL (High Density Lipoprotein) 
cholesterol (HDL-C) were measured in duplicate by standard enzymatic techniques (Synchron CX9 Pro, 
Beckman Coulter, Inc. Fullerton, CA, USA); LDL cholesterol (LDL-C) was calculated according to Friedewald 
et al. [26]. Hematocrit, complete blood count and differential were determined in K3EDTA-anticoagulated 
blood samples using an automated Coulter counter (model MAXM, Instrumentation Laboratory, Miami, FL, 
USA), with a sample size of up to 8000 cells. Acute phase reactant proteins (APRs) were assayed by rate 
nephelometry (BN- ProSpec, Siemens Healthcare Diagnostics, Italy). 
Routine chemical clinical analyses were performed by standard methods with strict quality control. MPO 
serum levels were measured by commercial ELISA assay (OxisResearch, OR, USA). All measurements were 
assayed in one batch on serum stored at -80°C. 
 
PMN isolation and immunofluorescence. Polymorphonuclear (PMN) cells were isolated from FH 
and healthy control peripheral blood by Ficoll/Hypaque (GE HealthCare, Amersham-Pharmacia) 
centrifugation, dextran sedimentation and erythrocytes hypotonic lysis [27]. PMN-rich supernatant was 
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used for immunofluorenscence analysis [28] using a first primary human antibody anti-MPO and a 
secondary antibody IgG conjugated to FITC  (Santa Cruz). 
Visual evaluation of immunofluorescence was performed by coupling the microscope AxioSkop 40 (Zeiss, 
Germany) to a digital camera AxioCam MRm (Zeiss). A FITC filter was used for the fluorescence wave-
length. Standard optical magnifications (20x and 100x) were used with a fixed exposure setting (color digital 
images were stored in JPEG format for off-line analysis). 
To quantitatively evaluate the fluorescence intensity in the cells, the acquired images were processed by 
the public domain Image Java application (National Institute of Health, Bethesda, MD, USA). 
Since  the pictorial information is virtually monochromatic, the intensity map of the image was studied 
according to an 8-bit dynamic (256 gray levels, 0 = black, 255 = white). The background luminescence 
intensity was measured inside the nucleus and subtracted. By means of threshold operations, the 
intracellular area (excluding the nucleus) was acknowledged and measured.  
Examples of the histograms obtained are shown in Fig. 1. In order to describe and  compare the grey level 
histograms, the mean and the standard deviation, related to the global brightness of the cell and to the 
overall contrast respectively, were measured in each image (see Appendix). 
 
Statistical Analysis. Data were expressed as mean ± Standard Error (SE). Variables showing no 
normal distribution, checked by Chi-squared test, were logarithmically transformed when appropriate. The 
parametric paired t-test was used to investigate the differences in mean of lipid profile, APRs and MPO 
between FH patients and controls. 
The partial Pearson Correlation coefficient was used to test the correlation between MPO, variable of lipid 
panel and APRs, removing the effects of the other confounding variables studied. 
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The Random Effects Linear Regression Model for repeated measures [29] was used to assess the effect of 
time on TC, time on MPO, TC on MPO; for each regression analysis, β-regression coefficient ± 2SE and p-
value was reported. The locally weighted scatterplot smoothing (LOWESS) technique [30] was used to 
further analyze the bivariate relationships between MPO and independent variables; this technique is 
designed to produce a smooth fit to the data and reduces the influence of extreme outliers. All  analyses 
were performed by the statistical package Stata 8 SE [31]. 
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Results 
 
Pre-treatment lipid profile, APRs and MPO concentrations of FH patients and healthy controls are 
shown in Table 1. As expected, compared to controls, patients’ lipid profiles were characterized by higher 
TC and LDL-C (p < 0.001); also, APR values were higher in FH than in controls; patients’ MPO concentrations 
resulted in a tenfold increase relative to controls. This latter condition was evident at the cellular level too: 
as shown in Fig. 1, patients’ PMN showed more intense azurophilic granules  compared to those isolated 
from healthy controls.  
Effect of LDL apheresis treatment. LDL apheresis treatment dramatically reduced lipid 
concentration: TC decreased from 343.1 ± 14.7 to 62.5 ± 9.2 mg/dl (-83%), LDL-C from 253.1 ± 16.9 to 28.9 
± 3.0 mg/dl (-90%) and TG from 196.1 ± 61.1 to 28.6 ± 5.6 mg/dl (-86%).  
Within 14 days all lipoproteins rebounded to pre-treatment values; TG regressed to baseline values within 
48 h. The TC time-course is shown in Fig. 2; the calculated TC increase was 20.69 ± 1.46 mg/dl per day (β 
regression coefficient 20.69 ± 2.92, p < 0.001). 
Routine laboratory tests, including complete blood count, resulted in normal range and did not change 
throughout the study. After LDL-A, MPO levels decreased from 20.4 ± 3.3 ng/dl to 12.9 ± 5.0 ng/ml (-36.3%, 
p < 0.0001), thereafter MPO increase was 0.48 ± 0.15 ng/dl per day (β regression coefficient 0.48 ± 0.30, p < 
0.005). MPO time-course is shown in Fig.  3. Rebound curves of TC and MPO had a similar pattern (Figs. 2 
and 3).  
The partial correlation between MPO, TC (LDL-C, TG and HDL-C were excluded by analysis due to the 
degree of high correlation with TC), APR variables and adhesion molecules, show that only TC had a 
significant effect on MPO levels (Table 2). 
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As a consequence, we performed a linear regression analysis between MPO and total cholesterol levels, 
showing a 0.022 ng/ml MPO increase for each 1 mg/dl TC increase (β regression coefficient 0.022 ± 0.010, p 
< 0.0001; Fig. 4).  
APRs and lipid factors were reduced after LDL-A treatment and showed a positive correlation with 
cholesterol values, as previously described [23, 32] throughout the study (data not shown). 
No difference was found between inlet and outlet MPO values. 
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Discussion  
 
  In this study we found that: 1) MPO serum levels are up-regulated in patients with FH  compared 
with controls; 2) decreased TC concentration with LDL apheresis is associated with  decreased MPO levels; 
3) the TC plasma concentration is the main determinant of MPO serum levels between the variables 
considered. 
All these data suggest that high TC levels could be a pathological condition leading to MPO up-regulation, 
by mechanisms that remain to be elucidated.  
Among FH patients, high MPO concentration further supports the hypothesis that hypercholesterolemia is 
a strong pro-inflammatory condition. Data  mainly refer to the relationship between high TC and the sub-
acute and long-lasting inflammation markers. 
 MPO is a marker of an acute inflammatory response. It is the main component of the first host defense and 
rapidly responds to stimuli.  MPO secretion leads to specific inflammatory pathways considered to be  links 
with clinical manifestation of acute coronary syndromes (production of oxidant hypochlorous acid, 
degradation of the atheroma fibrous cap and its increased vulnerability to erosion or rupture). 
The MPO reduction obtained upon LDL-A would strengthen the relation between TC and MPO 
concentration. The measured MPO reduction could be underestimated because heparin used during the 
extracorporeal circulation detached the MPO stuck on the artery wall, a well-known phenomenon [33] 
though not measured here. 
MPO serum levels do not return to the pre-treatment concentrations for up to 7 days, but rebound after 
LDL-A in a manner similar to cholesterol, further suggesting a close relationship  between the two variables.  
From the statistical analyses we excluded the values measured soon after the treatment in order to avoid 
bias due to: i) a possible non-specific MPO reduction via binding to dextran columns (although we found no 
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changes in MPO values from inlet and outlet dextran columns) and ii) the effects of leukocytes activation 
(as in other systems, such as the complement system) that occur during the interaction with extracorporeal 
circuits. Regarding  last point, it is important to recall that the leukocyte half-life is about 6 hours; upon 
their activation the MPO increases and not vice versa. The circulating leukocytes live 2 days after LDL-A, so 
they have no treatment memory, including their synthesis and secretion.  
The significant association between MPO and TC shown here  may not depend on the peculiarities of the 
clinical model used but instead  assume a general biological and clinical meaning. This consideration is 
supported by the wide range of plasma total cholesterol explored (from 60 to over 400 mg/dl) and by the 
linear MPO increase of 0.022 units for each 1 mg/dl TC increase. 
Changes seen (data not shown) in APRs listed in Table 1 are consistent with the interpretation of MPO 
being a principal actor in an acute and rapid inflammatory response (mediated by leukocytes). This is an 
important phenomenon within the intriguing process of  arterial wall vulnerability, and it is part of a larger 
inflammatory response that occurs in the high-cholesterol state. In our patients CRP levels were higher, 
though not significantly,  compared to controls, although lower than those of untreated 
hypercholesterolemic patients. This apparent contradiction may be explained by the long-lasting effect of 
LDL-A on chronically treated FH patients, which could have attenuated the inflammation [32].  
The  main study limitation is the lack of a causal relationship between  MPO concentration and  cholesterol 
levels, instead of simply a description of the phenomenon. Furthermore, the leucocyte MPO data provided 
by immunofluorescence are only qualitative. 
The relationship between TC and MPO as an index of leukocyte activation offers interesting biological  
possibilities, but surely more studies will be needed to elucidate the underling mechanisms. 
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Conclusions 
 
This study identifies a significant association between total plasma cholesterol levels and MPO in 
patients affected by Familial Hypercholesterolemia and suggests the possibility of modulating MPO plasma 
concentration by cholesterol levels. 
 14
Study limitations 
 
 The small number of patients chronically treated with LDL apheresis is a limitation of the present 
study and has to be acknowledged. There are few FH patients with clinical indication to LDL-A and only 
some of these patients had the pathophysiologic conditions to interrupt their pharmacological treatment 
for two months that is an appropriate period for management of statin-related side effects (like specified in 
Methods regard patients). 
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Appendix 
 
Imaging processing using the most recent tools and digital techniques aims to describe, by means of 
statistical approaches, the overall feature of the pictorial scene in terms of "tone", a concept related to the 
shades of grey of the elementary pictorial elements (pixels) of the digital representation. First order 
statistics is a lower-level approach, providing a wide variety of parameters for the quantitative description 
of the shape of the histogram of the grey level amplitude (tonal) distribution of the selected regions of 
interest. The simplest descriptors of the overall feature are given by typical parameters extracted from the 
grey level distribution (without considering spatial interdependencies). In particular, by considering the 
digital image as a matrix of equally sized pictorial elements (pixels), and by calling (gij) the grey level of the 
pixel of co-ordinates (i,j) inside the matrix of the region of interest R, and N the total number of grey values, 
the following features are defined : 
- the mean (m), which describes the average grey value of the distribution; it is related to the overall 
lightness/darkness of the pictorial data; in the specific case, it quantifies the average amplitude of 
immunofluorescence in the image. 
- standard deviation, that is the expression of spreading of distribution from the mean, i.e. the overall 
contrast. 
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Figure legends 
 
Fig. 1. MPO Immunofluorescence of PMN cells from FH patient and healthy control.  
Panel A. Fluorescence Microscope preparation of PMN cells from FH patient (left) and healthy 
control (right). Secondary FITC conjugated antibody was used against human anti- MPO antibody 
Panel B. Distribution of the pixel luminous intensity, described as histogram of the frequency of the 
brightness amplitude levels. 
 
Fig. 2. Relationship between total cholesterol and time.  
Locally weighted scatterplot smoothing (LOWESS) technique was used to fit the relationship 
between TC and time (p and β regression correlation). 
 
Fig. 3. Relationship between myeloperoxidase and time.  
Locally weighted scatterplot smoothing (LOWESS) technique was used to fit the relationships 
between MPO and time (p and β regression correlation). 
 
Fig. 4. Simple linear regression between MPO and TC.  
Random Effects Linear Regression Model for repeated measure (p and β regression correlation). 
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Tables 
Table 1. Lipid, acute phase reactans and myeloperoxidase concentrations in FH patients and controls. 
 
FH (n = 8) Controls (n = 8) * p-value 
Total Cholesterol (mg/dl) 343.1 ± 41.6 214.5 ± 32.0 <0.001 
Triglycerides (mg/dl) 196.1 ± 172.7 82.5 ± 41.4 ns 
High Density Lipoprotein (mg/dl) 50.9 ± 12.0 53.6 ± 10.5 ns 
Low Density Lipoprotein (mg/dl) 253.0 ± 47.7 144.4 ± 23.9 <0.001 
C Reactive Protein (mg/dl)  0.12 ± 0.08 0.08 ± 0.06 ns 
C3c complement fraction (mg/dl) 135.6 ± 22.1 92.6 ± 11.3 <0.001 
C4 complement fraction (mg/dl) 31.4 ± 15.7 19.6 ± 5.5 ns 
Haptoglobin (mg/dl) 114.6 ± 58.8 62.6 ± 26.5 <0.05 
α1-Antitrypsin (mg/dl) 151.7 ± 27.0 89.4 ± 12.3 <0.001 
α2-Macroglobulin (mg/dl) 183. ± 68.9 130.2 ± 31.5 <0.05 
α1-acid Glycoprotein (mg/dl) 81.5 ± 12.7 50.9 ± 4.7 <0.0001 
Ceruloplasmin (mg/dl) 24.2 ± 3.1 23.5 ± 6.7 ns 
Myeloperoxidase (ng/dl) 20.4 ± 3.3 1.9 ± 1.5 <0.01 
Values are mean ± SE,  *parametric paired t-test.  
 
Table 2. Partial MPO correlation with total cholesterol, acute phase reactans and adhesion molecules in FH 
patients. 
 β p-value 
Total cholesterol 0.3288 < 0.01 
C-Reactive protein 0.0247 ns 
C3c complement fraction  0.0025 ns 
C4 complement fraction  0.0748 ns 
Haptoglobin 0.1522 ns 
α1-Antitrypsin 0.0546 ns 
α2-Macroglobulin 0.1642 ns 
α1-acid glycoprotein 0.1808 ns 
Ceruloplasmin 0.0133 ns 
sICAM 0.1884 ns 
sELAM 0.1968 ns 
sVCAM 0.1183 ns 
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